HIV 4 year vaccine trials were unsuccessful
2023.01.18 14:15
HIV 4 year vaccine trials were unsuccessful
By Ray Johnson
Budrigannews.com – On Wednesday, Johnson & Johnson announced that the late-stage global trial of an HIV vaccine will be terminated due to its ineffectiveness in preventing infections.
The trial involved administering two distinct types of a shot that delivers the HIV genetic code through a cold-causing virus over four annual vaccination visits. (NYSE:) J&J used a technology that was similar for its COVID-19 vaccine.
In morning trading, shares of J&J were down 1% to $170.57. About 3,900 men who have sex with men and transgender people were included in the HIV vaccine study, which began in 2019 and was conducted at over 50 locations. These groups are thought to be at risk for the infection.
The HIV Vaccine Trials Network (HVTN), which is J&J’s partner, stated that the shot was only being tested on people who did not accept pre-exposure prophylaxis, which is treatment to prevent infections. The trial’s failure marks yet another setback in the search for a vaccine against HIV, a virus that is known to mutate rapidly and find novel ways to evade the immune system. The vaccine regimen did not have any safety issues, however.
Susan Buchbinder, co-chair of the HVTN study, stated, “Although HIV continues to prove uniquely challenging for development of a vaccine, the HIV research community remains fully committed to doing just that, and each study brings us a step closer to this realization.”
Despite the fact that no HIV vaccine has been tested and found to be safe, various drugs are used on patients and groups at high risk.
Throughout this time, several HIV vaccine candidates, including Moderna (NASDAQ:) The National Institute of Allergy and Infectious Diseases (NIAID), Inc., and HVTN are currently the subject of a trial.
In 2021, a mid-stage study involving a population of young women in sub-Saharan Africa for another HIV vaccine was unsuccessful.
